Krystal Biotech (NASDAQ:KRYS) Given “Buy” Rating at Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report released on Tuesday, Benzinga reports. They currently have a $204.00 price target on the stock, up from their prior price target of $178.00.

Other research analysts have also recently issued reports about the stock. William Blair restated an outperform rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Citigroup upped their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Finally, Guggenheim raised their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a research report on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of Buy and a consensus target price of $164.22.

Krystal Biotech Trading Down 3.3 %

KRYS stock opened at $163.97 on Tuesday. The stock has a market cap of $4.67 billion, a PE ratio of 2,049.88 and a beta of 0.85. The company has a 50-day moving average price of $158.80 and a 200 day moving average price of $129.73. Krystal Biotech has a 12 month low of $82.09 and a 12 month high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to analysts’ expectations of $27.43 million. During the same quarter in the previous year, the firm earned ($1.25) EPS. Sell-side analysts forecast that Krystal Biotech will post 1.61 EPS for the current year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 8,087 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the sale, the chief accounting officer now owns 12,556 shares in the company, valued at approximately $1,719,041.96. The disclosure for this sale can be found here. Insiders have sold a total of 40,587 shares of company stock worth $6,535,591 over the last 90 days. 14.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KRYS. Vanguard Group Inc. boosted its holdings in Krystal Biotech by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after purchasing an additional 35,632 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Krystal Biotech by 1.0% in the first quarter. BlackRock Inc. now owns 1,716,095 shares of the company’s stock worth $137,391,000 after buying an additional 16,499 shares during the last quarter. State Street Corp grew its holdings in Krystal Biotech by 52.3% during the first quarter. State Street Corp now owns 1,068,656 shares of the company’s stock worth $71,108,000 after acquiring an additional 366,855 shares during the period. Jennison Associates LLC raised its position in Krystal Biotech by 112.5% during the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after acquiring an additional 383,495 shares in the last quarter. Finally, First Light Asset Management LLC lifted its holdings in Krystal Biotech by 5.6% in the first quarter. First Light Asset Management LLC now owns 717,936 shares of the company’s stock valued at $47,771,000 after acquiring an additional 37,766 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).